Willem Hassel - Amgen Independent Vice Chairman of the Supervisory Board

AMG Stock  EUR 277.10  0.45  0.16%   

Chairman

Mr. Willem van Hassel was appointed Vice Chairman of the Supervisory Board of AMG Advanced Metallurgical Group N.V., effective as of May 2, 2018. He has served as Member of the Supervisory Board of the Company. He obtained his Law Degree at Erasmus University Rotterdam in 1964. Until 2000, for nearly 30 years, Mr. van Hassel has practised in various legal areas, amongst which company law in general, mergers and acquisitions, shareholders and board room disputes, reorganisations and bankruptcy cases, structuring of publicprivate partnerships and privatizations. During his legal career he has always combined his counseling activities with litigation, both in court cases and arbitration. He has acted as counsel to Dutch Parliament as well as the Dutch Accounting Office. In the early 1990s, he was president of the Netherlands Bar Association. During the last four years of his legal career he was chairman and managing partner of Trenit Van Doorne, at the time one of the Dutch leading law firms. Until 2000 he was also a Deputy Judge with the Rotterdam District Court. Furthermore Mr. van Hassel gets appointments by the Enterprise Chamber of the Court of Appeals in Amsterdam as an independent investigator temporary board member in mismanagement suits and shareholders deadlocks. In various capacities he is actively involved with the developments in the field of good governance. He is also editor of the Toolkit Commissariaat and serves and has served on various supervisory boards, including Eurocommercial Properties NV until recently. Mr. van Hassel furthermore served on the Board of the Foundation Continuity AMG until March 12th, 2017 when he resigned to prepare for his nomination for AMGs Supervisory Board. since 2018.
Age 73
Tenure 6 years
Phone805 447 1000
Webhttps://www.amgen.com

Amgen Management Efficiency

The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.
Amgen Inc has accumulated 37.35 B in total debt with debt to equity ratio (D/E) of 3.98, implying the company greatly relies on financing operations through barrowing. Amgen Inc has a current ratio of 1.28, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CHAIRMAN Age

Alexander StadlinPlaya Hotels Resorts
70
Bruce WardinskiPlaya Hotels Resorts
63
Anastassis DavidAEGEAN AIRLINES
48
Eftychios VassilakisAEGEAN AIRLINES
52
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. AMGEN INC operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 24300 people. Amgen Inc (AMG) is traded on Frankfurt Exchange in Germany and employs 25,200 people.

Management Performance

Amgen Inc Leadership Team

Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, VP Officer
Robert Bradway, CEO Chairman
Peter Griffith, Ex CFO
Murdo Gordon, Ex Operations
Dagmar Bottenbruch, Independent Member of the Supervisory Board
Donatella Ceccarelli, Independent Member of the Supervisory Board
Nancy Grygiel, Sr Officer
Willem Hassel, Independent Vice Chairman of the Supervisory Board
Frank Lohner, Independent Member of the Supervisory Board
Herbert Depp, Independent Member of the Supervisory Board
Steve Hanke, Independent Chairman of the Supervisory Board
Jackson Dunckel, Member of the Management Board, Chief Financial Officer
Michele Fischer, Vice President IR Contact Officer
Esteban Santos, Ex Operations
Heinz Schimmelbusch, Chairman of the Management Board, Chief Executive Officer
Eric Jackson, Member of the Management Board and Presidentident of the AMG Processing Division, COO
Jonathan Graham, Gen VP
Mike Zahigian, VP Officer
David MD, Ex RD
Arvind Sood, VP Relations

Amgen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Amgen Stock

When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.